Novo Nordisk had modeled a 25% weight loss, raising concerns about the drug’s prospects as a potential top-tier obesity treatment. The trial also pointed to challenges with dose escalation ...

Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema ...

Investing.com -- Novo Nordisk (CSE:NOVOb) shares jumped over 9% on Monday, despite the company’s disappointing results for its experimental obesity treatment, CagriSema. This followed the release of ...

Novo Nordisk has announced its latest trial result for the new obesity drug, CagriSema, which disappointed investors and sent its share price plunging 20% in Denmark on Friday, the sharpest one ...

Shares in Ozempic maker Novo Nordisk tumbled after an experimental anti-obesity shot fell short of expectations. The shares fell more than 20% in Copenhagen, closing at their lowest since August 2023.

The experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7 percent in a late-stage trial, Reuters quoted Novo Nordisk as saying on Friday ...

CagriSema helped patients lose an average of 22.7 per cent of their body weight in a late-stage trial, Novo Nordisk said on Friday, only marginally beating the results of Mounjaro, a rival ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

He said Novo Nordisk would use insights from the trial “to further explore the additional weight loss potential of CagriSema.” Novo Nordisk’s stock fell about 19% in early Friday trading on ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off ...